NAD+ biology is real, but the booster story is too small. Here is why raising a biomarker is not the same as restoring tissue function or slowing aging.
The market sells NAD+ as something to refill. Aging biology points to a stressed system of synthesis, recycling, consumption and tissue-specific demand.
NAD+ has become one of the cleanest stories in the longevity market.
The story usually goes like this: NAD+ declines with age. NAD+ matters for energy, DNA repair and healthy cells. So if aging lowers NAD+, take a precursor such as NR or NMN and restore what time has taken away.
It is simple. It is memorable. It gives the reader one job.
It is also too small for the biology.
The important part is that the first half of the story is not fake. NAD+ really is central to human metabolism. It participates in redox chemistry, mitochondrial energy handling, DNA repair signaling, sirtuin biology, immune signaling and cellular stress responses. NAD+ levels and NAD-related measures often decline with age, although the pattern varies by tissue and measurement method. Human studies also show that oral NAD+ precursors such as nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN, can raise NAD-related biomarkers in blood or immune-cell compartments (Covarrubias et al., 2021; Freeberg et al., 2023; Martens et al., 2018; Igarashi et al., 2022).
That matters.
But raising a marker is not the same thing as restoring a tissue. Restoring a tissue is not the same thing as slowing biological aging. And moving a pathway is not the same thing as proving a whole-body longevity benefit.
The better question is not only, “Can we raise NAD+?” In many cases, the answer appears to be yes.
The better question is: what kind of NAD+ system are we raising it into?
A low tank is easy to market. A stressed biological economy is harder to sell, but closer to the science. NAD+ is not just a number on a dashboard. It is made, recycled, consumed, degraded, redistributed and used differently depending on the tissue, the stress state and the biological context.
So when this article asks whether the problem is a “low tank” or a “leaky system,” the phrase is a metaphor. It does not mean NAD+ is literally leaking out of cells. It means aging may involve a NAD+ economy under pressure: less efficient synthesis, strained salvage, higher enzymatic consumption, inflammation, DNA repair demand, mitochondrial stress and tissue-specific need.
This is not a miracle story. But it is not nothing either.
The science gives us a strong reason to care about NAD+ biology. It gives us reasonable evidence that some precursors can move NAD-related biomarkers. It does not yet give us proof that NAD+ supplements broadly rejuvenate human tissues, improve healthspan or slow aging.
That gap between marker and meaning is where the real story begins.
What NAD+ actually does in the body
NAD+ is often described as a “cellular energy molecule.” The phrase is not wrong, but it can become slippery.
In marketing language, “cellular energy” can mean almost anything: less fatigue, sharper focus, better skin, faster recovery, healthier aging, longer life. Biology is more specific. It is also more interesting.
NAD+ has two major identities. It is a redox molecule involved in energy metabolism. It is also a signaling substrate consumed by enzymes involved in stress-response biology.
Those two roles are why NAD+ matters. They are also why a simple refill story breaks down.
NAD+ as an energy and redox molecule
At the most basic level, NAD+ helps cells move electrons.
NAD+ can accept electrons and become NADH. NADH can then donate electrons into metabolic pathways that help generate ATP, the cell’s usable energy currency. This redox cycling connects NAD+ to glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation, which are core parts of energy metabolism and mitochondrial function (Covarrubias et al., 2021).
That does not mean NAD+ works like caffeine. It does not simply pour energy into tired cells.
A better way to think about it is this: NAD+ helps maintain the chemical traffic that allows cells to extract energy from nutrients and manage redox balance. When that traffic is disrupted, mitochondrial metabolism and cellular resilience can suffer. When the system is supported, some parts of metabolism may work better, depending on the tissue and context.
That last phrase matters: depending on the tissue and context.
A blood marker may rise. A metabolic pathway may be engaged. But a muscle cell, liver cell, immune cell and brain cell do not all tell the same story just because one circulating marker changed.
NAD+ as a signaling substrate
NAD+ is not only recycled in energy metabolism. It is also consumed.
Several enzyme families use NAD+ as a substrate. These include sirtuins, PARPs, CD38 and, in specific neurobiology contexts, SARM1. These enzymes connect NAD+ to gene regulation, DNA damage responses, immune and calcium signaling, axonal degeneration and cellular stress biology (Covarrubias et al., 2021; Camacho-Pereira et al., 2016; Covarrubias et al., 2020).
This is where the tank metaphor starts to weaken.
If NAD+ were only a fuel-like molecule, the public story would be easier. Aging lowers the level. Add a precursor. Fill the tank.
But NAD+ is also spent during stress responses. PARPs consume NAD+ during DNA repair signaling. CD38 can degrade NAD+ and is linked in mechanistic and preclinical literature to immune aging and inflammation. Sirtuins consume NAD+ during regulatory reactions related to metabolism, stress responses and chromatin biology.
Those pathways are not decorative science words. They show why NAD+ can be low for more than one reason.
A cell may have less NAD+ because it produces less. It may recycle less efficiently. It may consume more during repair or inflammatory stress. It may distribute NAD-related metabolites differently across compartments. A blood marker may rise while a target tissue does not meaningfully recover function.
NAD+ is not just stored. It is used.
That changes the question.
Why the low tank metaphor is useful, but incomplete
The low tank metaphor exists because it explains something real. NAD+ often declines with age, and precursors can sometimes raise NAD-related markers.
As a starting image, it works.
As a full biological model, it fails.
A tank suggests one container, one level and one obvious intervention. Biology gives us compartments, pathways, flux, feedback, tissue differences and demand.
NAD+ levels often decline with age
Age-related NAD+ decline is one reason this field deserves attention. Reviews of NAD+ biology describe age-associated decreases in NAD+ or NAD-related measures across several tissues and experimental contexts, including human and preclinical evidence (Covarrubias et al., 2021; Freeberg et al., 2023).
That decline is biologically meaningful because NAD+ sits at the intersection of metabolism, repair, inflammation and stress adaptation.
But “NAD+ declines with age” does not mean every tissue simply runs out of NAD+ in the same way. It also does not prove that low NAD+ is the single cause of aging.
Aging is not one failure. It is a network of failures and compensations: mitochondrial stress, chronic low-grade inflammation, DNA damage, senescence, immune remodeling, metabolic inflexibility and loss of tissue resilience. NAD+ touches many of those processes, but it does not replace them.
So yes, the low tank story captures a real signal.
It just stops too early.
A pool is not the same thing as a flux
One of the most useful distinctions in NAD+ biology is the difference between a pool and a flux.
A NAD+ pool is a measured amount in a compartment. That compartment might be whole blood, plasma, PBMCs, muscle, liver or another tissue. It is the number you can report.
Flux is the movement through the system. It includes synthesis, salvage, conversion, consumption, degradation, recycling and tissue distribution.
The public conversation loves pools because pools are easy to market. This product raised NAD+ by a certain amount. This marker went up. This pathway was engaged.
Flux is messier. It asks where the NAD+ came from, where it went, what consumed it, whether recycling worked, whether the tissue that matters changed and whether the change translated into function.
That distinction is central.
A higher NAD-related blood marker can be meaningful evidence that a precursor reached the system and engaged NAD+ metabolism. But it does not automatically show that muscle mitochondria improved, brain cells were protected, skin aged more slowly or immune resilience was restored.
A biomarker can tell us the pathway was touched. It cannot, by itself, tell us the body was rejuvenated.
What “leaky system” should mean here
“Leaky system” is a metaphor, not a literal claim.
It does not mean NAD+ is physically leaking through cell membranes. It does not mean one enzyme is draining the whole body. It does not mean there is a single hidden cause of aging that can be plugged with the right supplement.
In this article, a “leaky system” means dysregulated NAD+ homeostasis.
It means the system may be under pressure from several directions at once: lower synthesis, weaker salvage, increased consumption, inflammatory signaling, DNA repair demand, mitochondrial stress and tissue-specific mismatch.
Think of it less like a gas tank and more like a household budget under stress.
You can increase income, and that may help. But if expenses are rising, recycling is inefficient, certain rooms need more power than others and the wiring is aging, income alone may not restore the whole house.
That is closer to how NAD+ fits into aging biology.
The useful question is not only how to raise NAD+. It is why the system is losing control of NAD+ in the first place.
The NAD+ economy: supply, salvage, recycling and demand
Once NAD+ is framed as an economy, precursors become easier to interpret.
They are not magic. They are not irrelevant. They are inputs.
The key question is what the input enters.
A precursor entering a resilient system may mean something different from a precursor entering a system under chronic inflammatory stress, metabolic dysfunction, tissue damage or disease-related NAD+ disruption.
The supply side: precursors are inputs
The body can make NAD+ through several routes.
Tryptophan can contribute through de novo synthesis. Nicotinic acid, also known as niacin, enters through the Preiss-Handler pathway. Nicotinamide can be recycled through the salvage pathway. NR and NMN enter related NAD+ salvage routes, although their absorption, conversion and tissue handling in humans are still being clarified (Bieganowski & Brenner, 2004; Covarrubias et al., 2021).
The details are fascinating, but this mother article does not need to become a pathway lecture.
The core idea is simpler: NAD+ precursors are not all the same molecule, but they become meaningful only after the body absorbs, converts, distributes and uses them.
That is why the “best booster” question is too narrow.
A molecule can raise a marker and still fail to produce a meaningful functional outcome. Another precursor may be useful in a specific disease or deficiency-like context but not translate into broad healthy-aging claims. A third may look impressive in animal models and more modest in humans.
The precursor is the input. The system decides the meaning.
The salvage side: recycling matters
Much of mammalian NAD+ biology depends on salvage.
When NAD+ is consumed by signaling enzymes, nicotinamide is produced. The salvage pathway can recycle nicotinamide back toward NAD+ through enzymes such as NAMPT and NMNAT. This recycling system helps maintain NAD+ availability without relying only on new dietary input (Covarrubias et al., 2021).
That matters because aging may not only reduce the amount of NAD+. It may affect the ability to keep NAD+ cycling efficiently.
If salvage capacity is strained, adding precursor input may raise some markers but still not solve every downstream problem. If tissue demand is high, the added input may be quickly used. If a target tissue does not receive or use the precursor effectively, blood markers may overstate the functional story.
This does not make precursors useless. It makes them context-dependent.
A refill can help when supply is limiting. It may be less impressive when the problem also involves recycling, consumption, tissue access or biological demand.
The demand side: NAD+ is spent under stress
NAD+ is not only made and recycled. It is spent.
PARPs consume NAD+ during DNA damage responses. CD38 is a NADase connected to immune-cell biology and has been implicated in age-related NAD+ decline in mechanistic and preclinical work. Sirtuins use NAD+ in regulatory reactions connected to stress responses, metabolism and gene regulation (Camacho-Pereira et al., 2016; Covarrubias et al., 2020; Covarrubias et al., 2021).
This demand side is one of the most important reasons the refill story is incomplete.
Aging is not just a lower-supply state. It can also be a higher-demand state.
Chronic low-grade inflammation, senescent-cell signaling, oxidative stress, DNA repair demand and immune remodeling may all increase pressure on NAD+ metabolism. In that setting, low NAD+ may be partly a sign of biological spending.
The body may be using NAD+ to respond to stress, repair damage, regulate inflammation and maintain function.
So the question becomes sharper.
Is the system low because it lacks input? Because recycling is weaker? Because consumption is higher? Because a tissue is under stress? Because the marker we measure does not represent the tissue we care about?
The answer may differ by person, tissue and condition.
That is why a universal booster story is biologically unsatisfying.
What human studies show, and what they do not show
The human evidence is not empty. It is also not as strong as the marketing often implies.
The cleanest way to read the field is as a ladder.
The biology is strong. Biomarker movement is real, especially for NR and increasingly for NMN. Functional outcomes are mixed, modest or context-specific. Human healthspan and longevity benefit are not established.
That is not a dismissal. It is the difference between a measurable event and a life-history claim.
NR and NMN can raise NAD-related biomarkers
Human studies support that NR can raise NAD-related biomarkers in whole blood, PBMCs or related metabolite pools. Trials and dose-response studies have reported increases in NAD+ or related metabolites after NR supplementation, with short-term tolerability generally reassuring in the study contexts reviewed (Martens et al., 2018; Conze et al., 2019; Freeberg et al., 2023).
Human evidence for NMN is smaller but growing. Studies in older men and selected metabolic contexts suggest NMN can increase blood NAD-related markers, with preliminary functional or metabolic signals that need confirmation in larger and more definitive trials (Igarashi et al., 2022; Yoshino et al., 2021; Irie et al., 2020; Freeberg et al., 2023).
This is meaningful evidence.
It means these compounds can engage the NAD+ pathway in humans. They are not just theoretical molecules from animal studies.
But pathway engagement is the beginning of interpretation, not the end.
Biomarker movement is not the same as tissue rejuvenation
A biomarker is a clue. It is not the whole case.
When a NAD-related marker rises in blood, plasma or PBMCs, it tells us something important: the intervention reached at least part of the system and altered measurable NAD+ metabolism.
That does not prove the same change happened in skeletal muscle, liver, brain, skin or immune tissue in a way that improved function.
This distinction matters because many public NAD+ claims move too quickly from marker to body-wide promise. They imply that if blood NAD+ rises, the whole body is more energetic, better repaired, metabolically younger or biologically rejuvenated.
That is not how translational biology works.
A signal in the blood can be useful. It can show exposure. It can show pathway engagement. It can help researchers compare interventions.
But tissue function is harder.
Can the marker reflect the tissue that matters? Does the tissue change? Does the change improve mitochondrial function, insulin sensitivity, vascular function, inflammatory tone, muscle performance or resilience? Does that effect persist? Is it clinically meaningful?
Most public NAD+ content stops too early in that chain.
Functional outcomes are mixed, modest or context-specific
Some human studies show signals worth taking seriously.
For example, NR studies have reported biomarker changes and, in some contexts, exploratory signals involving vascular measures, tissue metabolomics or inflammatory signatures. NMN studies have reported NAD-related biomarker increases and preliminary signals involving insulin sensitivity or muscle-related measures in selected populations (Martens et al., 2018; Elhassan et al., 2019; Igarashi et al., 2022; Yoshino et al., 2021).
But other trials show the central caution clearly: markers can move without meaningful functional improvement.
Dollerup et al. reported that NR supplementation in obese insulin-resistant men increased NAD-related metabolites but did not improve insulin sensitivity or several other metabolic outcomes over the study period (Dollerup et al., 2018). Elhassan et al. reported changes in the skeletal muscle NAD+ metabolome and inflammatory signatures in older men, but not a clear improvement in muscle mitochondrial function or physical performance endpoints in that small trial (Elhassan et al., 2019).
That is why the answer should not be reduced to “NAD+ boosters do nothing.” That is too blunt.
A better interpretation is this:
NAD+ precursors can move biology. The harder question is whether that movement becomes meaningful function in the tissue and person we care about.
That answer is still context-specific.
A rare mitochondrial disease context, a metabolically impaired group, a healthy middle-aged adult, a frail older adult and a biohacker with normal baseline function are not the same biological problem. Niacin in a mitochondrial myopathy context, for example, is not the same story as general longevity supplementation for healthy adults (Pirinen et al., 2020).
The evidence is not one flat “yes” or “no.” It is a ladder.
| Claim level | Evidence strength | What the evidence supports | What the evidence does not support |
|---|---|---|---|
| NAD+ biology in aging | Strong | NAD+ is central to energy, repair and stress-response pathways | NAD+ is the single cause of aging |
| Age-related NAD+ decline | Moderate to strong | NAD+ often declines with age, with tissue variability | Every tissue simply runs out of NAD+ |
| NR/NMN biomarker increase | Strong for NR, moderate and growing for NMN | These precursors can raise NAD-related markers | Biomarker rise proves rejuvenation |
| Functional outcomes | Mixed, preliminary, context-specific | Some signals exist in selected studies and populations | Broad healthspan benefit is proven |
| Human longevity or anti-aging | Very weak | Not established | NAD+ precursors slow aging in humans |
| Delivery superiority | Very weak | Treat premium delivery claims cautiously | IV, liposomal or patch formats are superior for aging outcomes |
This table is the article in miniature.
The science gives a real biomarker story. It does not yet give a broad human rejuvenation story.
Why NR vs NMN is not the mother question
People want the molecule war because it feels practical.
NR or NMN? Which is more direct? Which absorbs better? Which raises NAD+ more? Which is newer? Which is safer? Which one did the longevity person on the podcast recommend?
Those are not meaningless questions. They are just not the mother question.
The mother question is: what biological problem is the precursor entering?
Different precursors, same bigger problem
NR, NMN, niacin and nicotinamide enter NAD+ biology through different routes. Those differences can matter for pharmacokinetics, tolerability, tissue handling, metabolite patterns and research interpretation.
But molecule differences do not erase the larger system problem.
Even if a precursor raises a NAD-related marker, we still need to ask where the marker rose, whether the target tissue changed, whether function improved and whether the effect matters compared with context, risk, cost and alternatives.
A winner in a pathway diagram is not automatically a winner in human aging.
That is why this mother article should not become an NR vs NMN comparison. That question deserves its own satellite article because it requires careful handling of absorption, metabolism, regulation, study design and commercial framing.
For this piece, the main point is simpler:
Different precursors may enter through different doors, but they still walk into the same aging house.
If the house is under stress, the door is not the whole story.
Niacin is the unglamorous control case
Niacin is useful because it makes the marketing story more honest.
Nicotinic acid, commonly known as niacin, is a real vitamin B3 form and a real NAD+ precursor. It is not new, glamorous or wrapped in the same longevity branding as NR and NMN. It is also limited by tolerability issues such as flushing and by safety concerns at pharmacologic doses.
That makes it less attractive as a clean wellness product.
But biologically, niacin reminds us that NAD+ precursor science did not begin with the modern longevity market. The body has multiple ways to make NAD+, and older vitamin B3 biology still matters.
Pirinen et al. reported that niacin increased NAD+ measures and improved some outcomes in a small mitochondrial myopathy context, which is very different from claiming niacin is a general anti-aging supplement for healthy adults (Pirinen et al., 2020).
This distinction is useful.
A precursor can be clinically meaningful in a specific pathological or deficiency-like context without becoming a universal longevity tool.
That is one of the most important lessons in this field.
Delivery hype should not replace physiology
The NAD+ market does not stop at molecules. It also sells routes.
IV NAD+. Direct NAD+. Liposomal NAD+. Sublingual forms. Patches. Premium delivery formats.
The implied message is often simple: if the route sounds more advanced, the biology must be more powerful.
That is not enough.
Delivery matters when it changes exposure, tissue availability, safety, adherence or outcomes. But a delivery story is not a healthspan outcome. It does not prove tissue rejuvenation. It does not bypass the need to show meaningful function.
For this mother article, the delivery section should stay brief. It is a future satellite topic.
The key point is that route-of-administration hype can distract from the deeper physiological question. Getting something into the body is not the same as proving what it does once biology takes over.
A better way to interpret NAD+ claims
A good NAD+ claim should not stop at “raises NAD+.”
That may be an important step, but it is not the whole chain.
The reader needs a way to slow the claim down without becoming cynical. The goal is not to dismiss every NAD+ intervention. The goal is to ask what level of proof the claim has actually reached.
The six-question evidence chain
When you hear a NAD+ claim, ask:
- Can the precursor reach the system?
- Can it raise a relevant NAD-related marker?
- Does that marker reflect the tissue that matters?
- Does the tissue change translate into function?
- Does function translate into healthspan or resilience?
- Is the effect meaningful compared with context, risk, cost and alternatives?
Most public NAD+ content answers question 2 and speaks as if it answered question 6.
That is the shortcut.
A more serious interpretation recognizes each step. A precursor may be absorbed but not strongly affect the target tissue. A marker may rise but function may not change. A function may change modestly in one group but not support broad anti-aging claims. A signal may be interesting and still not worth the cost, risk or attention for every person.
Emerging longevity science is best treated this way: not closed, not credulous, not impressed by a single biomarker.
The useful question is not whether NAD+ matters. It does.
The useful question is what problem the precursor is entering, what evidence shows it changes and whether that change matters.
Safety belongs inside the interpretation
Safety should not be treated as a tiny disclaimer after the interesting biology. It is part of the interpretation.
NR and NMN have generally looked well tolerated in the short-term human studies reviewed, especially at the doses and durations used in trials. That is reassuring. It is not the same thing as a lifetime safety record.
Long-term high-dose use, pregnancy, active cancer, significant liver or kidney disease, complex medication use and frailty are not settled well enough for broad public advice. Niacin also deserves separate caution because pharmacologic doses can cause flushing and may raise liver, glucose or medication-context concerns.
The practical point is simple: NAD+ precursor science should not be read as a universal self-experiment. For people with medical conditions or complex medication use, this is a clinician conversation, not a podcast protocol (Freeberg et al., 2023; Radenkovic et al., 2020).
Lifestyle belongs inside the biology, not at the end as moral advice
Many cautious NAD+ articles end with lifestyle advice: exercise, sleep, diet, stress management.
That can feel like a polite way to say, “Do the boring things.”
Lifestyle should not be tacked on as moral advice. It belongs inside the biology.
Exercise, sleep, circadian rhythm, metabolic health, inflammation and nutrient status may influence the NAD+ economy by changing demand, salvage, mitochondrial stress and resilience. These factors shape the system a precursor enters.
That does not mean lifestyle “boosts NAD+” in a simple anti-aging way. It means the NAD+ economy is embedded in physiology.
A body under chronic inflammatory stress is not the same as a body with better metabolic flexibility. A sleep-disrupted system is not the same as a well-synchronized circadian system. A sedentary muscle is not the same as a trained muscle that regularly adapts to energetic demand.
This matters because NAD+ biology is not floating in isolation. It sits inside the broader aging network of mitochondria, inflammation, repair, immune signaling and resilience.
The supplement question cannot be separated from the system question.
Who might respond is still an open question
One of the most important unanswered questions is not “Do NAD+ precursors work?”
It is: for whom, in which tissue, under what biological conditions and compared with what else?
Healthy adults, older adults, frail adults, metabolically impaired individuals and people with disease-related NAD+ disruptions may not respond the same way. Baseline NAD+ status, inflammation, mitochondrial demand, tissue access and metabolic health may all matter.
Responder profiles are not settled.
This uncertainty is not a weakness to hide. It is the direction the field needs to move.
A more credible future for NAD+ science is not a universal booster for everyone. It is a more precise understanding of when NAD+ metabolism is truly limiting, which tissues are affected, which biomarkers are meaningful and whether an intervention changes function.
That is a better scientific question than “Which booster is best?”
NAD+ biology is real, but the booster story is too small
NAD+ deserves attention.
It sits close to energy metabolism, redox balance, DNA repair signaling, sirtuin biology, immune aging, mitochondrial stress and cellular resilience. Age-related NAD+ decline is a meaningful biological signal. NR and NMN can raise NAD-related biomarkers in humans. That is enough to make the field scientifically interesting.
It is not enough to make NAD+ precursors proven anti-aging tools.
The central mistake in public NAD+ content is not that it talks about NAD+. The mistake is that it compresses a complex aging economy into a refill story.
Aging does not look like one empty tank. It looks like a system under pressure.
Supply may change. Salvage may change. Consumption may rise. Inflammation may increase demand. DNA repair may spend more. Mitochondria may become less resilient. Blood markers may not speak for every tissue. Functional outcomes may appear in some contexts and fail in others.
That is the biology worth explaining.
NAD+ precursors are inputs into that system. Sometimes they clearly move markers. Sometimes they may produce useful signals. In specific disease or deficiency-like contexts, the story may be stronger. But broad claims about energy, cognition, skin, performance, whole-body rejuvenation and longevity are still ahead of the human evidence.
The mature interpretation is not cynicism.
It is precision.
NAD+ biology is real. Biomarker movement is real. Functional aging benefit remains unproven. Marketing often collapses those three statements into one promise.
A serious interpretation should not.
The market sells a refill. Biology asks what the system is doing with the refill.
That is the question that matters.
FAQ
Do NAD+ precursors slow aging?
Not based on current human evidence. NAD+ biology is strongly connected to metabolism, repair and stress-response pathways, and some precursors can raise NAD-related biomarkers. But a higher biomarker is not the same as proof that aging has slowed, tissues have been rejuvenated or healthspan has improved.
What are NAD+ precursors?
NAD+ precursors are compounds the body can use to make or recycle NAD+. They include vitamin B3-related molecules such as nicotinamide riboside, nicotinamide mononucleotide, niacin and nicotinamide, as well as tryptophan through a separate pathway. Their biological meaning depends on absorption, conversion, tissue handling, recycling and demand.
Is raising blood NAD+ the same as improving tissue function?
No. A blood or immune-cell marker can show that a precursor reached part of the NAD+ system. It does not automatically prove that skeletal muscle, liver, brain, skin or immune tissue improved in a meaningful way. That is the gap between biomarker movement and functional benefit.
Is NR better than NMN?
That question is too narrow for a mother article. NR and NMN enter NAD+ metabolism through related but different routes, and those differences can matter. But the bigger question is what biological problem the precursor is entering, whether the target tissue changes and whether the change improves function.
What does “leaky system” mean in this article?
It is a metaphor. It does not mean NAD+ is literally leaking out of cells. It means aging may involve dysregulated NAD+ homeostasis, where synthesis, salvage, recycling, consumption, inflammation, DNA repair demand and tissue-specific need all shape the system.
Are NAD+ precursors safe?
Short-term human studies of NR and NMN have generally looked reassuring within the doses and durations studied. That is not the same as a lifetime safety record. Long-term high-dose use, pregnancy, active cancer, significant liver or kidney disease, frailty and complex medication use should be treated as clinician-conversation territory. Niacin also needs separate caution because pharmacologic doses can cause flushing and may raise liver, glucose or medication-context concerns.
References
- Bieganowski, P., & Brenner, C. (2004). Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell, 117(4), 495-502. https://doi.org/10.1016/S0092-8674(04)00416-7
- Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., … & Chini, E. N. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006
- Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN nicotinamide riboside chloride in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://doi.org/10.1038/s41598-019-46120-z
- Covarrubias, A. J., Kale, A., Perrone, R., Lopez-Dominguez, J. A., Pisco, A. O., Kasler, H. G., … & Verdin, E. (2020). Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nature Metabolism, 2(11), 1265-1283. https://doi.org/10.1038/s42255-020-00305-3
- Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119-141. https://doi.org/10.1038/s41580-020-00313-x
- Dollerup, O. L., Christensen, B., Svart, M., Schmidt, M. S., Sulek, K., Ringgaard, S., … & Jessen, N. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: Safety, insulin-sensitivity, and lipid-mobilizing effects. The American Journal of Clinical Nutrition, 108(2), 343-353. https://doi.org/10.1093/ajcn/nqy132
- Elhassan, Y. S., Kluckova, K., Fletcher, R. S., Schmidt, M. S., Garten, A., Doig, C. L., … & Lavery, G. G. (2019). Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 28(7), 1717-1728.e6. https://doi.org/10.1016/j.celrep.2019.07.043
- Freeberg, K. A., Udovich, C. A. C., Martens, C. R., Seals, D. R., & Craighead, D. H. (2023). Dietary supplementation with NAD+-boosting compounds in humans: Current knowledge and future directions. The Journals of Gerontology: Series A, 78(12), 2435-2448. https://doi.org/10.1093/gerona/glad106
- Igarashi, M., Miura, M., Williams, E., Jaksch, F., Kadowaki, T., Yamauchi, T., & Guarente, L. (2022). Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj Aging and Mechanisms of Disease, 8, 5. https://doi.org/10.1038/s41514-022-00084-z
- Irie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., … & Itoh, H. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153-160. https://doi.org/10.1507/endocrj.EJ19-0313
- Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., … & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. https://doi.org/10.1038/s41467-018-03421-7
- Pirinen, E., Auranen, M., Khan, N. A., Brilhante, V., Urho, N., Pessia, A., … & Suomalainen, A. (2020). Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism, 31(6), 1078-1090.e5. https://doi.org/10.1016/j.cmet.2020.04.008
- Radenkovic, D., Reason, & Verdin, E. (2020). Clinical evidence for targeting NAD therapeutically. Pharmaceuticals, 13(9), 247. https://doi.org/10.3390/ph13090247
- Yoshino, M., Yoshino, J., Kayser, B. D., Patti, G. J., Franczyk, M. P., Mills, K. F., … & Klein, S. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. https://doi.org/10.1126/science.abe9985